These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 20551832)

  • 1. DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer.
    Becker JT; Olson BM; Johnson LE; Davies JG; Dunphy EJ; McNeel DG
    J Immunother; 2010; 33(6):639-47. PubMed ID: 20551832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase.
    Olson BM; Frye TP; Johnson LE; Fong L; Knutson KL; Disis ML; McNeel DG
    Cancer Immunol Immunother; 2010 Jun; 59(6):943-53. PubMed ID: 20140431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells.
    Johnson LE; Frye TP; Chinnasamy N; Chinnasamy D; McNeel DG
    Cancer Immunol Immunother; 2007 Jun; 56(6):885-95. PubMed ID: 17102977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer.
    McNeel DG; Dunphy EJ; Davies JG; Frye TP; Johnson LE; Staab MJ; Horvath DL; Straus J; Alberti D; Marnocha R; Liu G; Eickhoff JC; Wilding G
    J Clin Oncol; 2009 Sep; 27(25):4047-54. PubMed ID: 19636017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine.
    Wargowski E; Johnson LE; Eickhoff JC; Delmastro L; Staab MJ; Liu G; McNeel DG
    J Immunother Cancer; 2018 Mar; 6(1):21. PubMed ID: 29534736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP).
    Johnson LE; Frye TP; Arnot AR; Marquette C; Couture LA; Gendron-Fitzpatrick A; McNeel DG
    Vaccine; 2006 Jan; 24(3):293-303. PubMed ID: 16115700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination.
    Johnson LE; Olson BM; McNeel DG
    J Immunother Cancer; 2017 Jul; 5(1):56. PubMed ID: 28716080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of prostatic acid phosphatase (PAP) specific HLA-DR1-restricted T-cell epitopes.
    Johnson LE; McNeel DG
    Prostate; 2012 May; 72(7):730-40. PubMed ID: 22529020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic acid phosphatase in patients with castration-resistant prostate cancer.
    McNeel DG; Becker JT; Eickhoff JC; Johnson LE; Bradley E; Pohlkamp I; Staab MJ; Liu G; Wilding G; Olson BM
    Clin Cancer Res; 2014 Jul; 20(14):3692-704. PubMed ID: 24850844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bovine papillomavirus prostate cancer antigen virus-like particle vaccines are efficacious in advanced cancers in the TRAMP mouse spontaneous prostate cancer model.
    Simons BW; Cannella F; Rowley DT; Viscidi RP
    Cancer Immunol Immunother; 2020 Apr; 69(4):641-651. PubMed ID: 32016503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow up of patients treated with a DNA vaccine (pTVG-hp) for PSA-recurrent prostate cancer.
    Tonelli TP; Eickhoff JC; Johnson LE; Liu G; McNeel DG
    Hum Vaccin Immunother; 2024 Dec; 20(1):2395680. PubMed ID: 39208856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
    Machlenkin A; Paz A; Bar Haim E; Goldberger O; Finkel E; Tirosh B; Volovitz I; Vadai E; Lugassy G; Cytron S; Lemonnier F; Tzehoval E; Eisenbach L
    Cancer Res; 2005 Jul; 65(14):6435-42. PubMed ID: 16024648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel prostate acid phosphatase-based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour growth in mice.
    Saif JM; Vadakekolathu J; Rane SS; McDonald D; Ahmad M; Mathieu M; Pockley AG; Durrant L; Metheringham R; Rees RC; McArdle SE
    Eur J Immunol; 2014 Apr; 44(4):994-1004. PubMed ID: 24338683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA fusion gene vaccines induce cytotoxic T-cell attack on naturally processed peptides of human prostate-specific membrane antigen.
    Vittes GE; Harden EL; Ottensmeier CH; Rice J; Stevenson FK
    Eur J Immunol; 2011 Aug; 41(8):2447-56. PubMed ID: 21604260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma.
    Waeckerle-Men Y; Uetz-von Allmen E; Fopp M; von Moos R; Böhme C; Schmid HP; Ackermann D; Cerny T; Ludewig B; Groettrup M; Gillessen S
    Cancer Immunol Immunother; 2006 Dec; 55(12):1524-33. PubMed ID: 16612599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1.
    Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
    J Clin Immunol; 2007 Jan; 27(1):117-30. PubMed ID: 17180470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade.
    Olson BM; Jankowska-Gan E; Becker JT; Vignali DA; Burlingham WJ; McNeel DG
    J Immunol; 2012 Dec; 189(12):5590-601. PubMed ID: 23152566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide.
    Voutsas IF; Anastasopoulou EA; Tzonis P; Papamichail M; Perez SA; Baxevanis CN
    J Immunother Cancer; 2016; 4():75. PubMed ID: 27891225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterologous vaccination targeting prostatic acid phosphatase (PAP) using DNA and
    Johnson LE; Brockstedt D; Leong M; Lauer P; Theisen E; Sauer JD; McNeel DG
    Oncoimmunology; 2018; 7(8):e1456603. PubMed ID: 30221049
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.